You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Obinutuzumab

Showing 176 - 200 of 229
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lupus Nephritis Trial in Worldwide (Obinutuzumab, MMF, Prednisone)

Recruiting
  • Lupus Nephritis
  • Obinutuzumab
  • +6 more
  • Birmingham, Alabama
  • +146 more
May 20, 2021

Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

Not yet recruiting
  • Nephrotic Syndrome
  • Genova, Italy
    IRCCS G. Gaslini
Jan 19, 2023

Follicular Lymphoma Trial in Italy (Immunochemo regimen: Rituximab-bendamustine (Arm A), Immunochemo regimen:

Recruiting
  • Follicular Lymphoma
  • Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)
  • +9 more
  • Barletta, Barletta Andria Trani, Italy
  • +68 more
Oct 13, 2022

CD20 Positive Diffuse Large B-cell Lymphoma, Elderly Unfit Patients Trial in Italy (Ga101)

Terminated
Has Results
  • CD20 Positive Diffuse Large B-cell Lymphoma
  • Elderly Unfit Patients
  • Brescia, BS, Italy
  • +15 more
Nov 4, 2020

Solid Cancers Trial in Netherlands, United States (Atezolizumab, Bevacizumab, Interferon alfa-2b)

Completed
  • Solid Cancers
  • Scottsdale, Arizona
  • +8 more
May 11, 2020

Follicular Lymphoma, DLBCL Trial in Worldwide (Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin)

Completed
Has Results
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Obinutuzumab
  • +3 more
  • Los Angeles, California
  • +40 more
Feb 20, 2020

Diffuse Large B-cell Lymphoma Trial in Worldwide (Obinutuzumab, Glofitamab, Rituxumab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Obinutuzumab
  • +5 more
  • Birmingham, Alabama
  • +77 more
Jul 25, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Rituximab, Obinutuzumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Los Angeles, California
  • +86 more
Jan 23, 2023

Non-Hodgkin's Lymphoma Trial in United States (DCDS0780A, Rituximab, Obinutuzumab)

Completed
  • Non-Hodgkin's Lymphoma
  • Duarte, California
  • +6 more
Aug 27, 2019

Richter Syndrome Trial in New Hyde Park (Obinutuzumab, Ibrutinib, CHOP)

Terminated
  • Richter Syndrome
  • Obinutuzumab
  • +2 more
  • New Hyde Park, New York
    Northwell Health/CLL Research and Treatment Program
Feb 19, 2019

Chronic Lymphocytic Leukemia Trial (ibrutinib, obinutuzumab)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • (no location specified)
Jan 23, 2019

Lymphoma, Non-Hodgkin Trial in Worldwide (Venetoclax, Cyclophosphamide, Obinutuzumab)

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • Fullerton, California
  • +51 more
May 26, 2020

B- and T-cell Repertoire and Immune Response in Acute and

Recruiting
  • COVID-19
    • Washington, District of Columbia
    • +3 more
    Jan 24, 2023

    HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer Trial in United States (PRS-343)

    Completed
    • HER2-positive Breast Cancer
    • +3 more
    • Tucson, Arizona
    • +9 more
    Jan 18, 2022

    Infusion Reaction, Monoclonal Antibody Trial in Clovis (Montelukast 10 Mg Oral Tablet)

    Recruiting
    • Infusion Reaction
    • Monoclonal Antibody
    • Montelukast 10 Mg Oral Tablet
    • Clovis, California
      Community Cancer Institute
    Nov 8, 2021

    CLL/SLL Trial in Belgium, Denmark, Netherlands (Venetoclax/Acalabrutinib)

    Recruiting
    • CLL/SLL
    • Brussels, Belgium
    • +17 more
    Mar 22, 2022

    CLL/SLL Trial in Wuhan, Changsha (Orelabrutinib and BG)

    Not yet recruiting
    • CLL/SLL
    • Orelabrutinib and BG
    • Wuhan, Hubei, China
    • +1 more
    Jun 15, 2023

    Waldenstrom Macroglobulinemia Trial in Wroclaw, Poznan (Obinutuzumab 25 MG/ML)

    Recruiting
    • Waldenstrom Macroglobulinemia
    • Obinutuzumab 25 MG/ML
    • Wrocław, Dolnośląskie, Poland
    • +1 more
    Nov 9, 2018

    Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

    Not yet recruiting
    • Mantle Cell Lymphoma Refractory
    • (no location specified)
    May 16, 2023

    Retention Rate of Acalabrutinib in a Non-interventional Setting

    Recruiting
    • Chronic Lymphocytic Leukaemia (CLL)
      • Zittau, Germany
        Research Site
      Jan 12, 2023

      Solid Tumors Trial in Worldwide (RO6958688, Obinutuzumab, Tocilizumab)

      Completed
      • Solid Tumors
      • Los Angeles, California
      • +20 more
      Apr 15, 2020

      Chronic Lymphocytic Leucemia Trial in Cologne (Bendamustine, GA101, Ibrutinib)

      Completed
      • Chronic Lymphocytic Leucemia
      • Cologne, Germany
        German CLL Study Group
      May 7, 2019

      Chronic Lymphocytic Leukemia Trial in Worldwide (Idelalisib, Chlorambucil, Obinutuzumab)

      Terminated
      Has Results
      • Chronic Lymphocytic Leukemia
      • Santa Barbara, California
      • +17 more
      Oct 19, 2018

      Diffuse, Large B-Cell, Lymphoma Trial in Italy (GA101_DHAP)

      Completed
      • Diffuse, Large B-Cell, Lymphoma
      • Vicenza, VI, Italy
      • +9 more
      Mar 3, 2022

      Leukemia, Lymphocytic, Chronic, B-Cell Trial in Tours (GA101, Ibrutinib, Cyclophosphamide)

      Completed
      • Leukemia, Lymphocytic, Chronic, B-Cell
      • Tours, France
        Sponsor FILO
      Feb 14, 2019